Page 24 - Zyme Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Metrion Biosciences Appoints Mark Keogh as Non-Executive Director Appointment strengthens the financial and corporate experience of Metrion's Board in support of the Company's planned international growth Metrion Biosciences Limited ("Metrion"), the specialist ion channel contract research and drug discovery company, today announced the appointment of Mark Keogh as a Non-Executive Director. The appointment follows the Company's recently announced £2.7m new equity investment led by Gresham House Ventures and is intended to strengthen the Board's financial and corporate experience, in support ...

Posted on 388 ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and NUVISAN Innovation Campus Berlin (ICB) GmbH, a fully integrated contract research service provider for drug discovery and early development programs, today announced a non-exclusive license agreement granting NUVISAN ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio. NUVISAN ICB originated from a spin-out of the major pharma R&D functions of BAYER, wh...

Axol Bioscience and Censo Biotechnologies Announce Merger 03/17/2021 | 05:27am EDT Send by mail : Message : iPSC industry-leaders combine tools, talent, and technologies to drive life science discovery forward Merger accompanied by £3.8million ($5.3m USD) investment across shareholders, which will be used to fund recruitment and growth of the business Axol Bioscience Ltd, an established provider of iPSC-derived cells, media, and characterization services, and CENSO Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies, today announced that the two companies ...

CN Bio introduces the PhysioMimix OOC Multi-Organ Microphysiological System Expands portfolio of easy-to-use, robust and reliable human-relevant in vitro models, for fast-tracked drug discovery and development System to be launched at Society of Toxicology's 2021 Virtual Annual Meeting, 12 th 26 th March 2021 CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix OOC Multi-Organ MPS. The next-generation platform combines CN Bio's in vitro 3D liver model, who...

  Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.   The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the r...